A. Colmenarejo
9 Papers
204 Citations
A. Colmenarejo is an academic researcher. The author has contributed to research in topics: Tegafur & Regimen. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study.
Manuel González-Barón,J. Feliu,I. de la Gándara,Enrique Espinosa,A. Colmenarejo,B. Martínez-Martínez,E. Blanco,C. García-Girón,F. Juárez,Pilar Garrido,Amalio Ordóñez,P. Zamora +11 more
TL;DR: Oral UFT modulated by oral LV is active in advanced CRC and can be administered on an outpatient basis with no significant toxicity requiring hospitalisation, and should be thoroughly studied and compared with 5-fluorouracil modulated with leucovorin.
83
Uracil and Tegafur Modulated with Leucovorin An Effective Regimen with Low Toxicity for the Treatment of Colorectal Carcinoma in the Elderly
Juan M. Feliu,M. González Barón,Eugenia Espinosa,C. García Girón,I. de la Gándara,J. Espinosa,A. Colmenarejo,J. I. Jalon,Yoel Fernández,J. de Castro +9 more
TL;DR: In this article, the combination of uracil and tegafur (UFT) with leucovorin (LV) was shown to be effective and well tolerated in patients with advanced colorectal carcinoma.
69
•Journal Article
Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal.
González Barón M,J. Feliu,Amalio Ordóñez,A. Colmenarejo,Espinosa E,P. Zamora,de la Gándara I,J. I. Jalon +7 more
TL;DR: Twenty-six patients with advanced colorectal cancer were treated with UFT and leucovorin and three out of 24 evaluable patients achieved a partial response and 1 a complete response with U FT doses of 260 to 390 mg/m2.
25
UFT® Modulated with Leucovorin in Advanced Colorectal Cancer: Oncopaz Experience
M. González Barón,Jaime Feliu,C. García Girón,Javier Cassinello Espinosa,Brezo Martínez,Elodie Blanco,M.C. Crespo,Amalio Ordóñez,Enrique Espinosa,J. de Castro,F. Juárez,A. Colmenarejo +11 more
TL;DR: This regimen was active and well tolerated in patients with advanced colorectal cancer, including those 70 years of age or older, and there were no deaths due to toxicity.
19
Comparison of two chemotherapeutic regimens − mitomycin + vindesine 4-cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP) − in advanced non-small-cell lung cancer
M. González Barón,Juan M. Feliu,Eugenia Espinosa,C. García Girón,Elodie Blanco,Pilar Garrido,A. Colmenarejo,Amalio Ordóñez,A. Moyano,I. de la Gándara,P. Zamora +10 more
TL;DR: Given the low efficacy of both schemes in the treatment of advanced NSCLC, their use cannot be recommended outside of clinical trials.
12